$KYMR

$114.84 +$4.08 (3.68%) Close

$KYMR Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Ownership

13F as of Q2 2026 · 83.2M shares outstanding

Who owns KYMR?

By type of holder

Institutions 100.0% Insiders 0.0% Everyone else 0.0%

Concentration Top 10 holders own 93.0%

FMR LLC 14.9% · Baker Bros. Advisors (GP) LLC 10.4%

Institutional ownership

100.0%

0 pts vs last qtr

Institutional holders

274

+18 vs last qtr

Net shares bought

+694.7K

by institutions in Q2 2026

New / sold out

48 / 30

positions opened vs closed

How is ownership changing?

Institutions, last 8 quarters

Biggest buyers in Q2 2026

Price T Rowe Associates Inc /MD/ +1.1M
T. Rowe Price Investment Management, Inc. +792.3K

Biggest sellers in Q2 2026

Atlas Venture Life Science Advisors, LLC −1.7M
BVF Inc/il −1.6M

Who is planning to sell?

Notices of proposed sale, last 12 months

$490M

67 notices from 19 people

Shares covered

4.7M

5.67% of the company

Arranged in advance

56%

of the value is under a 10b5-1 plan

Under a 10b5-1 plan No plan

Largest proposed sellers

BVF Partners L P/il Affiliate of director $190M
Atlas Venture Fund X, LP Shareholder 10b5-1 $172M

Every notice on Red Flags →

A Form 144 is notice of a planned sale, not the sale itself. What insiders actually sold is on Insider Transactions.

Is your stake being diluted?

Diluted share count, FY2020–FY2025

+387.0%

+37.25% a year

Each share's claim on the business

−79.5%

shrank without buying or selling a share

Spent on buybacks vs paid in stock

— vs $224M

over 6 fiscal years

Diluted shares, split-adjusted

Buybacks Stock-based comp

How patient are the owners?

Institutional shares by how long they've been held

5+ years62% 3–5 years13% 1–3 years19% Under 1 year6%

Quarterly turnover

8.0%

of institutional shares changed hands

Top 10 managers, median time held

5 years

Super Investors

Investment managers reporting KYMR on Form 13F

Holder	Shares	% of company	Change vs last qtr	Held since	% of their book
F FMR LLC	12.3M	14.85%	+649.3K (+5.5%)	≤2021	0.1%
Shares held by quarter Peak holding12.3M (Q2'26) Change over 8 quarters+7.2M Share of the company14.850% FMR LLC's full portfolio →
BB Baker Bros. Advisors LP 13D · 10.9%	8.7M	10.41%	Unchanged	≤2021	5.0%
Shares held by quarter Peak holding8.7M (Q4'25) Change over 8 quarters+2.7M Share of the company10.410% Disclosed stake13D · 10.9% Baker Bros. Advisors LP's full portfolio →

FMR LLC

12.3M

% of company

14.85%

Change vs last qtr

+649.3K (+5.5%)

Held since

≤2021

Baker Bros. Advisors LP

13D · 10.9%

8.7M

% of company

10.41%

Change vs last qtr

Unchanged

Held since

≤2021

28 more super investors behind a free account

See every manager holding Kymera Therapeutics, Inc., how their position has changed, and how long they've held it.

Institutional Funds

Mutual funds and ETFs reporting KYMR on Form N-PORT; together they hold 49.3% of the company

Fund	Position value	Shares	% of company	% of the fund	As of
FG Fidelity Growth Company Fund Fidelity Mt. Vernon Street Trust	$266M	2.2M	2.70%	0.27%	August 31, 2026
TR T. Rowe Price New Horizons Fund, Inc. T. Rowe Price New Horizons Fund, Inc.	$259M	2.3M	2.71%	1.76%	June 30, 2026

Fidelity Growth Company Fund

Fidelity Mt. Vernon Street Trust

Position value

$266M

% of company

2.70%

% of the fund

0.27%

As of

August 31, 2026

T. Rowe Price New Horizons Fund, Inc.

Position value

$259M

% of company

2.71%

% of the fund

1.76%

As of

June 30, 2026

23 more funds behind a free account

See every fund holding Kymera Therapeutics, Inc. and how much of the fund the position is.

Insiders and 5%+ holders

From Forms 3/4/5 and Schedules 13D/G

Holder	Shares	% of company	Change vs last qtr	8 quarters	Held since	% of their book
BB Baker Bros. Advisors (GP) LLC 5%+ holder 13D · 10.9%	8.7M	10.44%	—	—	—	—
This holder reports through Schedule 13D/G, not a quarterly 13F. Share of the company10.440% Disclosed stake13D · 10.9% View the 13D/G filing →
JC Julian C. Baker 5%+ holder 13D · 10.9%	8.7M	10.44%	—	—	—	—
This holder reports through Schedule 13D/G, not a quarterly 13F. Share of the company10.440% Disclosed stake13D · 10.9% View the 13D/G filing →

Baker Bros. Advisors (GP) LLC

5%+ holder13D · 10.9%

8.7M

% of company

10.44%

Change vs last qtr

—

Held since

—

Julian C. Baker

5%+ holder13D · 10.9%

8.7M

% of company

10.44%

Change vs last qtr

—

Held since

—

21 more holders behind a free account

See every insider and 5%+ holder of Kymera Therapeutics, Inc..

Comments